PhocusWright Conference Honors Magicstay.Com With Launch People's Choice Award
26.11.2019 16:28:00 EET | Business Wire | Press release
On Thursday, November 21, MagicStay won the Launch People's Choice Award at the Phocuswright Conference in Fort Lauderdale, Florida - the world's leading event showcasing the latest technological trends in tourism.
This prestigious award, a veritable acknowledgement of the entire tourism and mobility sector, is a reflection of MagicStay's development strategy, which was put into effect over the past two years on a global scale. With this award, MagicStay has established itself as a key player in Business Travel and mobility on the international stage.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191126005486/en/
A special prize for a special team! #MagicTeam (Photo: Business Wire)
MagicStay, winner of the Launch People's Choice Award
The Launch People's Choice Award recognizes companies which are at least 4 years old and have come up with an innovation that revolutionizes the travel industry. Through this award, the Phocuswright Conference showcases the latest trends and technological innovations in the main sectors of the travel market every year.
In a 10-minute pitch, William Lecerf, co-founder of MagicStay, was able to impress the Dragons - the ten members of the Jury. He received nine positive endorsements in front of around 2,000 of the most influential international experts from the travel industry. The prize was presented to William Lecerf, co-founder (on the left), Valéry Linyer, co-founder and CEO (in the center) and Slobodan Petrovic, COO (on the right).
These 2,000 experts then elected MagicStay.com ahead of twelve competitors previously selected by Phocuswright: Affirm, Airdna, Amadeus, Arrivalist, Cover Genius, HotelRunner, Left Travel, Mistifly, Nezasa, Sift, Kiwi or Travelcompsitor. The prize was awarded jointly to MagicStay.com and Kiwi.
The Dragons' comments were very complimentary:
"You are building a database which offers unique value that no-one else has managed to develop".
Will Philippson,
former Co-founder and COO SilveRail Technologies
"I really like the fact that your content is available in the SBTs".
Charuta Fadnis,
Senior Director Product Strategy and Analytics BCD Travel
"As an expat looking for accommodation in a foreign country, anything you can do to simplify this process is absolutely fantastic. It's an infernal procedure that companies spend a lot of time dealing with and your solution is BRILLANT".
Philip Wolf,
Serial Board Director and Founder Phocuswright Inc.
"I was really impressed by your Duty of Care presentation. As a large company, I know that this issue is one of the biggest fears we have to face when sending our employees abroad on assignments".
Gayle Knolls,
Head of Business Development TRAVELPORT
An effective development strategy
Launched in 2013 in Grasse, the www.MagicStay.com platform devoted its first five years of business to R&D.
After initially focusing on the market of trade show organizers, since 2016 MagicStay has been offering business travelers and, since the beginning of this year, expatriates and/or persons on professional mobility assignments, a secure alternative to professional hotels by responding to duty of care challenges, traveler safety demands and personal data protection, required by large companies.
While broadening its scope, the hosting platform dedicated to professionals has doubled its offer since the beginning of the year. It now has more than 600,000 apartments, villas or apart-hotels available throughout the world (in more than 3,000 cities and 130 countries).
In 2020, MagicStay hopes to reach one million hosting units.
The photo on the previous page and other photos are available on request
MagicStay media library (press releases, logo, photo gallery, etc.)
Join us on: Facebook Twitter LinkedIn
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191126005486/en/
Contact information
MagicStay press contacts:
Fabienne Frédal (AB3C)
Tel. +33 (0)1 53 30 74 07 - fabienne@ab3c.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom